Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cu HAT-2DG-ES
- Development stage
- Preclinical
- Lead developer
- Institute of Drug Discovery and Design, Zhejiang University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**Cu HAT-2DG-ES** is an experimental, intravenously evaluated copper-based nanotube nanomedicine developed for preclinical hepatocellular carcinoma treatment. It consists of a copper-HAT nanotube loaded with 2-deoxy-D-glucose and the copper ionophore elesclomol. The system combines glycolytic starvation, copper-ionophore-driven cuproptosis, and copper-mediated Fenton-like chemodynamic therapy: released copper depletes glutathione, increases reactive oxygen species, disrupts mitochondrial metabolism, and promotes aggregation of lipoylated mitochondrial proteins including DLAT. In mouse hepatocellular carcinoma models, the formulation produced tumor-growth inhibition and prolonged survival relative to comparator nanotube formulations. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12407334/))
- Other names
- Cu HAT-2DG-ESCuHAT-2DG-ESCuHAT2DG-ESCuHAT 2DG-ES
02
Targets
OGDH (Dihydrolipoamide S-succinyltransferase)DLAT (Dihydrolipoamide S-acetyltransferase)
Beyond the preview
Go deeper on Cu HAT-2DG-ES.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cu HAT-2DG-ES.